We have immunized advanced melanoma patients with a HLA-A2-compatible human melanoma line genetically modified to release interleukin-2 (IL-2), to elicit or increase a T cell-mediated anti-melanoma response that may affect distant lesions. Twelve stage-IV patients were injected subcutaneously at days 1, 13, 26, and 55 with IL-2 gene-transduced and irradiated melanoma cells at doses of 5 or 15 x 10(7) cells. Both local and systemic toxicities were mild, consisting of transient erythema at the vaccination site; fever occurred in a minority of patients. Three mixed responses were recorded. Seven patients were evaluable for immunological studies. Mixed tumor-lymphocyte cultures carried out with different allogeneic HLA-A2-matched melanoma lines...
Cancer vaccines have recently been shown to induce some clinical benefits. The relationship between ...
Abstract Background Adoptive cell therapy may be based on isolation of tumor-specific T cells, e.g. ...
Many antigens recognized by autologous T lymphocytes have been identified on human melanoma. Melanom...
We have immunized advanced melanoma patients with a HLA-A2-compatible human melanoma line geneticall...
A human melanoma line genetically modified to release interleukin 4 (IL-4) was utilized to immunize ...
From January 1994 to July 1996 we immunized metastatic melanoma patients with HLA-A2-compatible, int...
We have established a model for the immunologic rejection of melanoma cells. Using a receptor-mediat...
Patients with stage I-III melanoma were vaccinated with the modified HLA-A2-binding gp100(209-2M)-pe...
Summary Clinical observations in the interleukin (IL) 2-based immunotherapies suggest that T cells p...
Although melanoma accounts for only 4% of skin cancers, it is responsible for 80% of deaths from ski...
Purpose: The progressive immune dysfunctions that occur in patients with advanced melanoma make them...
Tumor specific immunity is mediated by cytotoxic T lymphocytes (CTL) that recognize peptide antigen ...
Tumor specific immunity is mediated by cytotoxic T lymphocytes (CTL) that recognize peptide antigen ...
The frequency and function of regulatory T cells (Tregs) were studied in stage II-III melanoma patie...
Previous studies indicated that peripheral blood lymphocytes from patients (Pt-PBL) with lymph node ...
Cancer vaccines have recently been shown to induce some clinical benefits. The relationship between ...
Abstract Background Adoptive cell therapy may be based on isolation of tumor-specific T cells, e.g. ...
Many antigens recognized by autologous T lymphocytes have been identified on human melanoma. Melanom...
We have immunized advanced melanoma patients with a HLA-A2-compatible human melanoma line geneticall...
A human melanoma line genetically modified to release interleukin 4 (IL-4) was utilized to immunize ...
From January 1994 to July 1996 we immunized metastatic melanoma patients with HLA-A2-compatible, int...
We have established a model for the immunologic rejection of melanoma cells. Using a receptor-mediat...
Patients with stage I-III melanoma were vaccinated with the modified HLA-A2-binding gp100(209-2M)-pe...
Summary Clinical observations in the interleukin (IL) 2-based immunotherapies suggest that T cells p...
Although melanoma accounts for only 4% of skin cancers, it is responsible for 80% of deaths from ski...
Purpose: The progressive immune dysfunctions that occur in patients with advanced melanoma make them...
Tumor specific immunity is mediated by cytotoxic T lymphocytes (CTL) that recognize peptide antigen ...
Tumor specific immunity is mediated by cytotoxic T lymphocytes (CTL) that recognize peptide antigen ...
The frequency and function of regulatory T cells (Tregs) were studied in stage II-III melanoma patie...
Previous studies indicated that peripheral blood lymphocytes from patients (Pt-PBL) with lymph node ...
Cancer vaccines have recently been shown to induce some clinical benefits. The relationship between ...
Abstract Background Adoptive cell therapy may be based on isolation of tumor-specific T cells, e.g. ...
Many antigens recognized by autologous T lymphocytes have been identified on human melanoma. Melanom...